About: Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19) Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
Creator	Carratalà, Jordi Berenguer, Juan Pachón, Jerónimo Arribas, José Arribas, Ramón Jarrín, Inmaculada Rodríguez-Baño, Jesús Ryan, Pablo Yllescas, María
Source	Elsevier; Medline; PMC
abstract	OBJECTIVES: The objective of this study was to estimate the association of tocilizumab and corticosteroids with the risk of intubation or death in COVID-19 patients with hyperinflammatory state according to clinical and laboratory parameters. METHODS: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 with clinical and laboratory data indicative of hyperinflammatory state. Main exposure was treatment with tocilizumab; intermediate-high dose of corticosteroids (IHDC); pulse dose of corticosteroids (PDC); combination therapy; or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTW). RESULTS: 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively were compared with 344 not treated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratio (odds ratio for combination therapy) for the primary endpoint were 0.32 (95% CI, 0.22-0.47; p<0.001) for tocilizumab, 0.82 (0.71-1.30; p=0.82) for IHDC, 0.61 (0.43-0.86; p=0.006) for PDC, and 1.17 (0.86-1.58; p=0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p<0.001). CONCLUSIONS: Tocilizumab might be useful in COVID-19 patients with hyperinflammatory state and should be prioritized for randomized trials.
has issue date	2020-08-27(xsd:dateTime)
bibo:doi	10.1016/j.cmi.2020.08.010
bibo:pmid	32860964
has license	no-cc
sha1sum (hex)	a6c272ebc3aa16a5db3296738a7239cb942754a7
schema:url	https://doi.org/10.1016/j.cmi.2020.08.010
resource representing a document's title	Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)
has PubMed Central identifier	PMC7449935
has PubMed identifier	32860964
schema:publication	Clin Microbiol Infect
resource representing a document's body	covid:a6c272ebc3aa16a5db3296738a7239cb942754a7#body_text
is schema:about of	named entity 'Fever' named entity 'ferritin' named entity 'patients' named entity 'corticosteroids' named entity 'cohort study' named entity 'Treatment' named entity 'COVID-19' named entity 'INTERMEDIATE' named entity 'INTUBATION' named entity 'CORTICOSTEROIDS' named entity '95% CI' named entity 'intubation' named entity 'dose' named entity 'COVID-19' named entity 'patients' named entity 'Treatment' named entity 'RCT' named entity 'Corticosteroids' named entity 'Propensity scores' named entity 'Fever' named entity 'Corticosteroids' named entity 'oxygen' named entity 'COVID-19' named entity 'COVID-19' named entity 'corticosteroids' named entity 'corticosteroids' named entity 'COVID-19' named entity 'tocilizumab' named entity 'SAM' named entity 'tocilizumab' named entity 'proinflammatory cytokines' named entity 'observational studies' named entity 'primary endpoint' named entity 'tocilizumab' named entity 'severe pneumonia' named entity 'recombinant' named entity 'corticosteroids' named entity 'primary endpoint' named entity 'RCT' named entity 'host response' named entity 'dexamethasone' named entity 'asymptomatic' named entity 'observational studies' named entity 'invasive mechanical ventilation' named entity 'intubated' named entity 'Tocilizumab' named entity 'confidence intervals' named entity 'immune response' named entity 'retrospective cohort study' named entity 'coronaviruses' named entity 'propensity scores' named entity 'COVID' named entity 'Spain' named entity 'tocilizumab' named entity 'intubation' named entity 'primary endpoint' named entity 'case report' named entity 'tocilizumab' named entity 'observational studies' named entity 'D-dimer' named entity 'dexamethasone' named entity 'cohort study' named entity 'standard of care' named entity 'corticosteroids' named entity 'ferritin' named entity 'intubation' named entity 'd-dimer' named entity 'Kaplan-Meier curves' named entity 'clinical situation' named entity 'oxygen support' named entity 'oxygen' named entity 'methylprednisolone' named entity 'IL6'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software